Treace Medical Concepts Statistics
Total Valuation
TMCI has a market cap or net worth of $311.27 million. The enterprise value is $270.52 million.
| Market Cap | 311.27M |
| Enterprise Value | 270.52M |
Important Dates
The last earnings date was Tuesday, May 7, 2024, after market close.
| Earnings Date | May 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
TMCI has 62.01 million shares outstanding. The number of shares has increased by 5.23% in one year.
| Shares Outstanding | 62.01M |
| Shares Change (YoY) | +5.23% |
| Shares Change (QoQ) | +0.14% |
| Owned by Insiders (%) | 27.45% |
| Owned by Institutions (%) | 68.42% |
| Float | 43.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.59 |
| Forward PS | 1.32 |
| PB Ratio | 2.46 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.38 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.98, with a Debt / Equity ratio of 0.55.
| Current Ratio | 3.98 |
| Quick Ratio | 2.98 |
| Debt / Equity | 0.55 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9.53 |
Financial Efficiency
Return on equity (ROE) is -39.70% and return on invested capital (ROIC) is -28.94%.
| Return on Equity (ROE) | -39.70% |
| Return on Assets (ROA) | -22.20% |
| Return on Capital (ROIC) | -28.94% |
| Revenue Per Employee | $379,905 |
| Profits Per Employee | -$106,103 |
| Employee Count | 516 |
| Asset Turnover | 0.80 |
| Inventory Turnover | 1.28 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -80.73% in the last 52 weeks. The beta is 0.37, so TMCI's price volatility has been lower than the market average.
| Beta (1Y) | 0.37 |
| 52-Week Price Change | -80.73% |
| 50-Day Moving Average | 10.65 |
| 200-Day Moving Average | 12.19 |
| Relative Strength Index (RSI) | 27.97 |
| Average Volume (30 Days) | 946,775 |
Short Selling Information
The latest short interest is 3.04 million, so 4.91% of the outstanding shares have been sold short.
| Short Interest | 3.04M |
| Short Previous Month | 2.76M |
| Short % of Shares Out | 4.91% |
| Short % of Float | 6.99% |
| Short Ratio (days to cover) | 9.46 |
Income Statement
In the last 12 months, TMCI had revenue of $196.03 million and -$54.75 million in losses. Loss per share was -$0.88.
| Revenue | 196.03M |
| Gross Profit | 158.76M |
| Operating Income | -56.62M |
| Pretax Income | -54.75M |
| Net Income | -54.75M |
| EBITDA | -40.79M |
| EBIT | -49.55M |
| Loss Per Share | -$0.88 |
Balance Sheet
The company has $110.01 million in cash and $69.25 million in debt, giving a net cash position of $40.76 million or $0.66 per share.
| Cash & Cash Equivalents | 110.01M |
| Total Debt | 69.25M |
| Net Cash | 40.76M |
| Net Cash Per Share | $0.66 |
| Equity / Book Value | 126.39M |
| Book Value Per Share | 2.04 |
| Working Capital | 140.35M |
Cash Flow
In the last 12 months, operating cash flow was -$24.54 million and capital expenditures -$13.91 million, giving a free cash flow of -$38.44 million.
| Operating Cash Flow | -24.54M |
| Capital Expenditures | -13.91M |
| Free Cash Flow | -38.44M |
| FCF Per Share | -$0.62 |
Margins
Gross margin is 80.99%, with operating and profit margins of -28.88% and -27.93%.
| Gross Margin | 80.99% |
| Operating Margin | -28.88% |
| Pretax Margin | -27.93% |
| Profit Margin | -27.93% |
| EBITDA Margin | -20.81% |
| EBIT Margin | -25.28% |
| FCF Margin | -19.61% |
Dividends & Yields
TMCI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.23% |
| Shareholder Yield | -5.23% |
| Earnings Yield | -17.59% |
| FCF Yield | -12.35% |
Analyst Forecast
The average price target for TMCI is $9.67, which is 93.40% higher than the current price. The consensus rating is "Hold".
| Price Target | $9.67 |
| Price Target Difference | 93.40% |
| Analyst Consensus | Hold |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 20.65% |
| EPS Growth Forecast (5Y) | -33.93% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TMCI has an Altman Z-Score of 1.55 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.55 |
| Piotroski F-Score | 1 |